+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Type 1 Diabetes Drug Market Research Report by Form (Insulin Therapy and Oral Medication), by End User (Drugstore and Hospital), by Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2026 - Cumulative Impact of COVID-19

  • ID: 4985893
  • Report
  • July 2021
  • Region: Global
  • 180 pages
  • 360iResearch™
UP TO OFF
until Sep 30th 2021
The Global Type 1 Diabetes Drug Market will Grow to USD 22.75 Billion by 2026, at a CAGR of 8.86%

FEATURED COMPANIES

  • Albireo
  • B.braun Melsungen AG
  • Diavacs, Inc.
  • Glaxosmithkline PLC
  • Macrogenics, Inc.
  • Novartis International AG
  • MORE
The Global Type 1 Diabetes Drug Market size was estimated at USD 13.66 Billion in 2020 and expected to reach USD 14.83 Billion in 2021, at a Compound Annual Growth Rate (CAGR) 8.86% to reach USD 22.75 Billion by 2026.



Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Type 1 Diabetes Drug to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Form, the Type 1 Diabetes Drug Market was examined across Insulin Therapy and Oral Medication. The Insulin Therapy was further studied across Long-Acting Insulin, Premix Analogs, and Rapid Acting Insulin. The Oral Medication was further studied across Biguanides and Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors.
  • Based on End User, the Type 1 Diabetes Drug Market was examined across Drugstore and Hospital.
  • Based on Geography, the Type 1 Diabetes Drug Market was examined across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas was further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific was further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, and Thailand. The Europe, Middle East & Africa was further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. This ongoing research amplifies this research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Type 1 Diabetes Drug Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Type 1 Diabetes Drug Market, including Albireo, Astellas Pharma Inc., Astrazeneca PLC, B.braun Melsungen AG, Biocon Limited, Bristol Myers Squibb, C.H. Boehringer Sohn AG & Ko. KG, DiaVacs, Inc., Diavacs, Inc., Eli Lilly and Company, Glaxosmithkline PLC, Janssen Pharmaceuticals, Johnson & Johnson Services, Inc., Lupin Limited, Macrogenics, Inc., Merck & Co., Inc., Mylan N.V., Novartis International AG, Novo Nordisk A/s, Pfizer Inc., Piramal Healthcare Limited, Samsung Bioepis Co., Ltd., Sanofi S.A., Teva Pharmaceutical Industries Ltd., and XOMA Corp.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Type 1 Diabetes Drug Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Type 1 Diabetes Drug Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Type 1 Diabetes Drug Market?
4. What is the competitive strategic window for opportunities in the Global Type 1 Diabetes Drug Market?
5. What are the technology trends and regulatory frameworks in the Global Type 1 Diabetes Drug Market?
6. What is the market share of the leading vendors in the Global Type 1 Diabetes Drug Market?
7. What modes and strategic moves are considered suitable for entering the Global Type 1 Diabetes Drug Market?
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Albireo
  • B.braun Melsungen AG
  • Diavacs, Inc.
  • Glaxosmithkline PLC
  • Macrogenics, Inc.
  • Novartis International AG
  • MORE
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary
3.1. Introduction
3.2. Market Outlook
3.3. Form Outlook
3.4. End User Outlook
3.5. Geography Outlook
3.6. Competitor Outlook

4. Market Overview
4.1. Introduction
4.2. Cumulative Impact of COVID-19

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing incidences of type 1 diabetes globally
5.1.1.2. Increasing healthcare expenditure with rising disposable income
5.1.1.3. Rising patient awareness on type 1 diabetes treatment
5.1.2. Restraints
5.1.2.1. Patent expiration of drugs
5.1.3. Opportunities
5.1.3.1. Emerging introduction of novel drugs to treat diabetes
5.1.3.2. Surge in research and development activities for type 1 anti-diabetic drugs
5.1.4. Challenges
5.1.4.1. Strict regulations for the approval drugs
5.2. Porters Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Threat of Substitutes
5.2.3. Bargaining Power of Customers
5.2.4. Bargaining Power of Suppliers
5.2.5. Industry Rivalry

6. Type 1 Diabetes Drug Market, by Form
6.1. Introduction
6.2. Insulin Therapy
6.2.1. Long-Acting Insulin
6.2.2. Premix Analogs
6.2.3. Rapid Acting Insulin
6.3. Oral Medication
6.3.1. Biguanides
6.3.1.1. Metformine
6.3.1.2. Metformine Extended-Release
6.3.2. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors
6.3.2.1. Canaglifozine
6.3.2.2. Dapagliflozine
6.3.2.3. Empagliflozine
6.3.2.4. Ertugliflozine

7. Type 1 Diabetes Drug Market, by End User
7.1. Introduction
7.2. Drugstore
7.3. Hospital

8. Americas Type 1 Diabetes Drug Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States

9. Asia-Pacific Type 1 Diabetes Drug Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Thailand

10. Europe, Middle East & Africa Type 1 Diabetes Drug Market
10.1. Introduction
10.2. France
10.3. Germany
10.4. Italy
10.5. Netherlands
10.6. Qatar
10.7. Russia
10.8. Saudi Arabia
10.9. South Africa
10.10. Spain
10.11. United Arab Emirates
10.12. United Kingdom

11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis
11.3. Market Share Analysis, By Key Player
11.4. Competitive Scenario
11.4.1. Merger & Acquisition
11.4.2. Agreement, Collaboration, & Partnership
11.4.3. New Product Launch & Enhancement
11.4.4. Investment & Funding
11.4.5. Award, Recognition, & Expansion

12. Company Usability Profiles
12.1. Albireo
12.2. Astellas Pharma Inc.
12.3. Astrazeneca PLC
12.4. B.braun Melsungen AG
12.5. Biocon Limited
12.6. Bristol Myers Squibb
12.7. C.H. Boehringer Sohn AG & Ko. KG
12.8. DiaVacs, Inc.
12.9. Diavacs, Inc.
12.10. Eli Lilly and Company
12.11. Glaxosmithkline PLC
12.12. Janssen Pharmaceuticals
12.13. Johnson & Johnson Services, Inc.
12.14. Lupin Limited
12.15. Macrogenics, Inc.
12.16. Merck & Co., Inc.
12.17. Mylan N.V.
12.18. Novartis International AG
12.19. Novo Nordisk A/s
12.20. Pfizer Inc.
12.21. Piramal Healthcare Limited
12.22. Samsung Bioepis Co., Ltd.
12.23. Sanofi S.A.
12.24. Teva Pharmaceutical Industries Ltd.
12.25. XOMA Corp.

13. Appendix
13.1. Discussion Guide
13.2. License & Pricing

List of Figures
FIGURE 1. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, 2020 VS 2026 (USD BILLION)
FIGURE 2. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2020 (USD BILLION)
FIGURE 3. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2020 (USD BILLION)
FIGURE 4. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2020 (USD BILLION)
FIGURE 5. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 6. GLOBAL TYPE 1 DIABETES DRUG MARKET: MARKET DYNAMICS
FIGURE 7. GLOBAL TYPE 1 DIABETES DRUG MARKET: PORTERS FIVE FORCES ANALYSIS
FIGURE 8. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2020 VS 2026 (%)
FIGURE 9. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2020 VS 2026 (USD BILLION)
FIGURE 10. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2026
FIGURE 11. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, 2018-2026 (USD BILLION)
FIGURE 12. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 13. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY LONG-ACTING INSULIN, 2018-2026 (USD BILLION)
FIGURE 14. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY LONG-ACTING INSULIN, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 15. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PREMIX ANALOGS, 2018-2026 (USD BILLION)
FIGURE 16. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PREMIX ANALOGS, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 17. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY RAPID ACTING INSULIN, 2018-2026 (USD BILLION)
FIGURE 18. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY RAPID ACTING INSULIN, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 19. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, 2018-2026 (USD BILLION)
FIGURE 20. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 21. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, 2018-2026 (USD BILLION)
FIGURE 22. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 23. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY METFORMINE, 2018-2026 (USD BILLION)
FIGURE 24. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY METFORMINE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 25. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY METFORMINE EXTENDED-RELEASE, 2018-2026 (USD BILLION)
FIGURE 26. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY METFORMINE EXTENDED-RELEASE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 27. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, 2018-2026 (USD BILLION)
FIGURE 28. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 29. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY CANAGLIFOZINE, 2018-2026 (USD BILLION)
FIGURE 30. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY CANAGLIFOZINE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 31. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DAPAGLIFLOZINE, 2018-2026 (USD BILLION)
FIGURE 32. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DAPAGLIFLOZINE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 33. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY EMPAGLIFLOZINE, 2018-2026 (USD BILLION)
FIGURE 34. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY EMPAGLIFLOZINE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 35. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ERTUGLIFLOZINE, 2018-2026 (USD BILLION)
FIGURE 36. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ERTUGLIFLOZINE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 37. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2020 VS 2026 (%)
FIGURE 38. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2020 VS 2026 (USD BILLION)
FIGURE 39. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2026
FIGURE 40. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DRUGSTORE, 2018-2026 (USD BILLION)
FIGURE 41. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DRUGSTORE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 42. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITAL, 2018-2026 (USD BILLION)
FIGURE 43. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITAL, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 44. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
FIGURE 45. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 46. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2026
FIGURE 47. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 48. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 49. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 50. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 51. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 52. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
FIGURE 53. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 54. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2026
FIGURE 55. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 56. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 57. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 58. INDONESIA TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 59. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 60. MALAYSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 61. PHILIPPINES TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 62. SINGAPORE TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 63. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 64. THAILAND TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 65. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
FIGURE 66. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
FIGURE 67. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2026
FIGURE 68. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 69. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 70. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 71. NETHERLANDS TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 72. QATAR TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 73. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 74. SAUDI ARABIA TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 75. SOUTH AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 76. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 77. UNITED ARAB EMIRATES TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 78. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
FIGURE 79. GLOBAL TYPE 1 DIABETES DRUG MARKET: FPNV POSITIONING MATRIX
FIGURE 80. GLOBAL TYPE 1 DIABETES DRUG MARKET: SHARE, BY KEY PLAYER, 2020
FIGURE 81. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL TYPE 1 DIABETES DRUG MARKET, BY TYPE

List of Tables
TABLE 1. GLOBAL TYPE 1 DIABETES DRUG MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016–2020
TABLE 3. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 4. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2026 (USD BILLION)
TABLE 5. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN THERAPY, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 6. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY LONG-ACTING INSULIN, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 7. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PREMIX ANALOGS, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 8. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY RAPID ACTING INSULIN, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 9. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL MEDICATION, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 10. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY BIGUANIDES, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 11. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY METFORMINE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 12. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY METFORMINE EXTENDED-RELEASE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 13. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SODIUM GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 14. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY CANAGLIFOZINE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 15. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DAPAGLIFLOZINE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 16. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY EMPAGLIFLOZINE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 17. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ERTUGLIFLOZINE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 18. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 19. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DRUGSTORE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 20. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITAL, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 21. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 22. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2026 (USD BILLION)
TABLE 23. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 24. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2026 (USD BILLION)
TABLE 25. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 26. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2026 (USD BILLION)
TABLE 27. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 28. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2026 (USD BILLION)
TABLE 29. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 30. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2026 (USD BILLION)
TABLE 31. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 32. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 33. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2026 (USD BILLION)
TABLE 34. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 35. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 36. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2026 (USD BILLION)
TABLE 37. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 38. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2026 (USD BILLION)
TABLE 39. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 40. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2026 (USD BILLION)
TABLE 41. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 42. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2026 (USD BILLION)
TABLE 43. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 44. INDONESIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2026 (USD BILLION)
TABLE 45. INDONESIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 46. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2026 (USD BILLION)
TABLE 47. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 48. MALAYSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2026 (USD BILLION)
TABLE 49. MALAYSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 50. PHILIPPINES TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2026 (USD BILLION)
TABLE 51. PHILIPPINES TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 52. SINGAPORE TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2026 (USD BILLION)
TABLE 53. SINGAPORE TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 54. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2026 (USD BILLION)
TABLE 55. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 56. THAILAND TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2026 (USD BILLION)
TABLE 57. THAILAND TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 58. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
TABLE 59. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2026 (USD BILLION)
TABLE 60. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 61. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2026 (USD BILLION)
TABLE 62. FRANCE TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 63. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2026 (USD BILLION)
TABLE 64. GERMANY TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 65. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2026 (USD BILLION)
TABLE 66. ITALY TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 67. NETHERLANDS TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2026 (USD BILLION)
TABLE 68. NETHERLANDS TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 69. QATAR TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2026 (USD BILLION)
TABLE 70. QATAR TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 71. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2026 (USD BILLION)
TABLE 72. RUSSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 73. SAUDI ARABIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2026 (USD BILLION)
TABLE 74. SAUDI ARABIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 75. SOUTH AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2026 (USD BILLION)
TABLE 76. SOUTH AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 77. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2026 (USD BILLION)
TABLE 78. SPAIN TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 79. UNITED ARAB EMIRATES TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2026 (USD BILLION)
TABLE 80. UNITED ARAB EMIRATES TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 81. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY FORM, 2018-2026 (USD BILLION)
TABLE 82. UNITED KINGDOM TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2026 (USD BILLION)
TABLE 83. GLOBAL TYPE 1 DIABETES DRUG MARKET: SCORES
TABLE 84. GLOBAL TYPE 1 DIABETES DRUG MARKET: BUSINESS STRATEGY
TABLE 85. GLOBAL TYPE 1 DIABETES DRUG MARKET: PRODUCT SATISFACTION
TABLE 86. GLOBAL TYPE 1 DIABETES DRUG MARKET: RANKING
TABLE 87. GLOBAL TYPE 1 DIABETES DRUG MARKET: SHARE, BY KEY PLAYER, 2020
TABLE 88. GLOBAL TYPE 1 DIABETES DRUG MARKET: MERGER & ACQUISITION
TABLE 89. GLOBAL TYPE 1 DIABETES DRUG MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 90. GLOBAL TYPE 1 DIABETES DRUG MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 91. GLOBAL TYPE 1 DIABETES DRUG MARKET: INVESTMENT & FUNDING
TABLE 92. GLOBAL TYPE 1 DIABETES DRUG MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 93. GLOBAL TYPE 1 DIABETES DRUG MARKET: LICENSE & PRICING
Note: Product cover images may vary from those shown
  • Albireo
  • Astellas Pharma Inc.
  • Astrazeneca PLC
  • B.braun Melsungen AG
  • Biocon Limited
  • Bristol Myers Squibb
  • C.H. Boehringer Sohn AG & Ko. KG
  • DiaVacs, Inc.
  • Diavacs, Inc.
  • Eli Lilly and Company
  • Glaxosmithkline PLC
  • Janssen Pharmaceuticals
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Macrogenics, Inc.
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis International AG
  • Novo Nordisk A/s
  • Pfizer Inc.
  • Piramal Healthcare Limited
  • Samsung Bioepis Co., Ltd.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • XOMA Corp.
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll